Over 100 drugs in clinical trials aim to transform age-related macular degeneration treatment by 2026

DelveInsight's 2026 report reveals more than 100 drugs in development for age-related macular degeneration (AMD), involving over 90 companies globally. These therapies include novel mechanisms like gene therapy, mitochondrial stabilization, and VEGF inhibitors, targeting both dry and wet AMD forms. Key players such as Merck, Sanofi, and Stealth BioTherapeutics are advancing late-stage trials, with some drugs nearing regulatory approval. This pipeline growth reflects rising demand for effective, durable vision-preserving treatments amid an aging population, signaling significant future market opportunities.